Insights Center
Thought leadership, news, events — you will find them all here, right at your fingertips. We’ve consolidated the firm’s most popular content in one, easy to search location. Enter a key word or phrase to find pertinent blog posts, articles, press releases, and upcoming events.
Mintz Direct
Mintz Viewpoints
Showing 8409 - 8416 of 12089 results
Post-Senate Vote, Major Food Manufacturers Choose to Label Genetically Engineered Foods
March 29, 2016| Blog| Viewpoint
Supreme Court Decides to Hear Samsung v. Apple, Appears Ready to Weigh-In on Patent Damage Calculations
March 28, 2016| Blog| Viewpoint
USCIS Guidance on "Same or a Similar" Occupation for AC21 Welcomed
March 28, 2016| Blog| Viewpoint
Burton III, Dickerson: Forget oil prices, renewables are here to stay
March 28, 2016| News
DOJ Aims Torpedo At FCA Sampling Suit In 4th Circ.
March 28, 2016| News
More Money, More Problems? – The Rise of Compensation and Expectations for College Coaches (Employment Matters)
March 28, 2016| Blog| Viewpoint
The Supreme Court’s Tyson Foods Ruling and Employee Class Actions
March 28, 2016| Alert| Viewpoint
National Retailer Settles FTC Native Advertising Complaint
March 26, 2016| Blog| Viewpoint
News & Press Releases
Mintz advised the creators of Morbid, one of the top-charting true crime podcasts, in a multi-year agreement to move to SiriusXM from Wondery. The deal gives SiriusXM exclusive advertising rights for the audio and video formats of the podcast.
Mintz Advises CVC DIF in Acquisition of SBA Communications’ Canadian Tower Infrastructure Platform
August 06, 2025
Mintz advised CVC DIF, the dedicated infrastructure investment strategy of global private markets manager CVC, in its agreement to acquire SBA Communications’ Canadian wireless tower business, one of Canada’s leading independent owners and operators of wireless communications towers. The transaction is expected to close in the fourth quarter of 2025, subject to customary closing conditions.
Mintz advised the underwriters in connection with a $69 million public offering by Larimar Therapeutics, Inc. of 21,562,500 shares of its common stock at a price to the public of $3.20 per share. The gross proceeds to Larimar from the offering were $69 million before deducting underwriting discounts and commissions and other offering expenses.
Events
Podcasts
Mintz On Air: Practical Policies — A Private Equity Non-Compete Primer
July 15, 2025| Podcast|
Health Law Diagnosed – Best Practices for Communicating with the FDA
July 9, 2025| Podcast|